Abstract
AbstractComplex machine learning models are poised to revolutionize the treatment of diseases like acute myeloid leukemia (AML) by helping physicians choose optimal combinations of anti-cancer drugs based on molecular features. While accurate predictions are important, it is equally important to be able to learn about the underlying molecular basis of anti-cancer drug synergy. Explainable AI (XAI) offers a promising new route for data-driven cancer pharmacology, combining highly accurate models with interpretable insights into model decisions. Due to the highly correlated, high-dimensional nature of cancer transcriptomic data, however, we find that existing XAI approaches are suboptimal when applied naively to large transcriptomic datasets. We show how a novel approach based on model ensembling helps to increase the quality of explanations. We then use our method to demonstrate that a hematopoietic differentiation signature underlies synergy for a variety of anti-AML drug combinations.
Publisher
Cold Spring Harbor Laboratory
Reference101 articles.
1. Acute myeloid leukaemia;Nature reviews Disease primers,2016
2. Kurtz, S. E. et al. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proceedings of the National Academy of Sciences, 201703094. http://www.pnas.org/content/early/2017/08/02/1703094114.abstract (Aug. 2017).
3. Approaches to modernize the combination drug development paradigm;Genome medicine,2016
4. An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies
5. Mechanisms of drug combinations: interaction and network perspectives
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献